Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 135 entries
Sorted by: Best Match Show Resources per page
Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Shimoi T, Noguchi E, Sudo K, Chua YJ, Yonemori K.
PMID: 34554822
J Clin Oncol. 2021 Nov 01;39(31):3519-3521. doi: 10.1200/JCO.21.01537. Epub 2021 Sep 23.

No abstract available.

Cite
Shimoi T, Noguchi E, Sudo K, et al. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy. J Clin Oncol. 2021;39(31):3519-3521doi: 10.1200/JCO.21.01537.
Shimoi, T., Noguchi, E., Sudo, K., Chua, Y. J., & Yonemori, K. (2021). Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(31), 3519-3521. https://doi.org/10.1200/JCO.21.01537
Shimoi, Tatsunori, et al. "Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,31 (2021): 3519-3521. doi: https://doi.org/10.1200/JCO.21.01537
Shimoi T, Noguchi E, Sudo K, Chua YJ, Yonemori K. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy. J Clin Oncol. 2021 Nov 01;39(31):3519-3521. doi: 10.1200/JCO.21.01537. Epub 2021 Sep 23. PMID: 34554822.
Copy Download .nbib Format: NLM
Action-dependent processing of self-motion in parietal cortex of macaque monkeys.

Journal of neurophysiology

Churan J, Kaminiarz A, Schwenk JCB, Bremmer F.
PMID: 34010579
J Neurophysiol. 2021 Jun 01;125(6):2432-2443. doi: 10.1152/jn.00049.2021. Epub 2021 May 19.

Successful interaction with the environment requires the dissociation of self-induced from externally induced sensory stimulation. Temporal proximity of action and effect is hereby often used as an indicator of whether an observed event should be interpreted as a result...

Cite
Churan J, Kaminiarz A, Schwenk JCB, et al. Action-dependent processing of self-motion in parietal cortex of macaque monkeys. J Neurophysiol. 2021;125(6):2432-2443doi: 10.1152/jn.00049.2021.
Churan, J., Kaminiarz, A., Schwenk, J. C. B., & Bremmer, F. (2021). Action-dependent processing of self-motion in parietal cortex of macaque monkeys. Journal of neurophysiology, 125(6), 2432-2443. https://doi.org/10.1152/jn.00049.2021
Churan, Jan, et al. "Action-dependent processing of self-motion in parietal cortex of macaque monkeys." Journal of neurophysiology vol. 125,6 (2021): 2432-2443. doi: https://doi.org/10.1152/jn.00049.2021
Churan J, Kaminiarz A, Schwenk JCB, Bremmer F. Action-dependent processing of self-motion in parietal cortex of macaque monkeys. J Neurophysiol. 2021 Jun 01;125(6):2432-2443. doi: 10.1152/jn.00049.2021. Epub 2021 May 19. PMID: 34010579.
Copy Download .nbib Format: NLM
Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics.

Preventive medicine

Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC.
PMID: 34762966
Prev Med. 2021 Nov 08;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08.

Since 2012, cervical cancer screening guidelines allow for choice of screening test for women age 30-65 years (i.e., Pap every 3 years or Pap with human papillomavirus co-testing every 5 years). Intended to give patients and providers options, this...

Cite
Haas JS, Cheng D, Yu L, et al. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2021;154:106871doi: 10.1016/j.ypmed.2021.106871.
Haas, J. S., Cheng, D., Yu, L., Atlas, S. J., Clark, C., Feldman, S., Silver, M. I., Kamineni, A., Chubak, J., Pocobelli, G., Tiro, J. A., & Kobrin, S. C. (2021). Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Preventive medicine, 154106871. https://doi.org/10.1016/j.ypmed.2021.106871
Haas, Jennifer S, et al. "Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics." Preventive medicine vol. 154 (2021): 106871. doi: https://doi.org/10.1016/j.ypmed.2021.106871
Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2021 Nov 08;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08. PMID: 34762966.
Copy Download .nbib Format: NLM
Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells.

Blood cancer discovery

Mian SA, Abarrategi A, Kong KL, Rouault-Pierre K, Wood H, Oedekoven CA, Smith AE, Batsivari A, Ariza-McNaughton L, Johnson P, Snoeks T, Mufti GJ, Bonnet D.
PMID: 33778768
Blood Cancer Discov. 2021 Mar;2(2):135-145. doi: 10.1158/2643-3230.BCD-20-0161. Epub 2020 Dec 23.

Myelodysplastic syndrome (MDS) are clonal stem cell diseases characterized mainly by ineffective hematopoiesis. Here, we present an approach that enables robust long-term engraftment of primary MDS stem cells (MDS-SCs) in mice by implantation of human mesenchymal cell-seeded scaffolds. Critically...

Cite
Mian SA, Abarrategi A, Kong KL, et al. Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. Blood Cancer Discov. 2020;2(2):135-145doi: 10.1158/2643-3230.BCD-20-0161.
Mian, S. A., Abarrategi, A., Kong, K. L., Rouault-Pierre, K., Wood, H., Oedekoven, C. A., Smith, A. E., Batsivari, A., Ariza-McNaughton, L., Johnson, P., Snoeks, T., Mufti, G. J., & Bonnet, D. (2021). Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. Blood cancer discovery, 2(2), 135-145. https://doi.org/10.1158/2643-3230.BCD-20-0161
Mian, Syed A, et al. "Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells." Blood cancer discovery vol. 2,2 (2021): 135-145. doi: https://doi.org/10.1158/2643-3230.BCD-20-0161
Mian SA, Abarrategi A, Kong KL, Rouault-Pierre K, Wood H, Oedekoven CA, Smith AE, Batsivari A, Ariza-McNaughton L, Johnson P, Snoeks T, Mufti GJ, Bonnet D. Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. Blood Cancer Discov. 2021 Mar;2(2):135-145. doi: 10.1158/2643-3230.BCD-20-0161. Epub 2020 Dec 23. PMID: 33778768; PMCID: PMC7610449.
Copy Download .nbib Format: NLM
Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics.

Preventive medicine

Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC.
PMID: 34762966
Prev Med. 2021 Nov 08;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08.

Since 2012, cervical cancer screening guidelines allow for choice of screening test for women age 30-65 years (i.e., Pap every 3 years or Pap with human papillomavirus co-testing every 5 years). Intended to give patients and providers options, this...

Cite
Haas JS, Cheng D, Yu L, et al. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2021;154:106871doi: 10.1016/j.ypmed.2021.106871.
Haas, J. S., Cheng, D., Yu, L., Atlas, S. J., Clark, C., Feldman, S., Silver, M. I., Kamineni, A., Chubak, J., Pocobelli, G., Tiro, J. A., & Kobrin, S. C. (2021). Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Preventive medicine, 154106871. https://doi.org/10.1016/j.ypmed.2021.106871
Haas, Jennifer S, et al. "Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics." Preventive medicine vol. 154 (2021): 106871. doi: https://doi.org/10.1016/j.ypmed.2021.106871
Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2021 Nov 08;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08. PMID: 34762966.
Copy Download .nbib Format: NLM
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.

Blood

Garcia-Manero G, Mufti Obe GJ, Fenaux P, Buckstein RJ, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS.
PMID: 34758066
Blood. 2021 Nov 10; doi: 10.1182/blood.2021012589. Epub 2021 Nov 10.

No abstract available.

Cite
Garcia-Manero G, Mufti Obe GJ, Fenaux P, et al. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2021;doi: 10.1182/blood.2021012589.
Garcia-Manero, G., Mufti Obe, G. J., Fenaux, P., Buckstein, R. J., Santini, V., Díez-Campelo, M., Finelli, C., Ilhan, O., Sekeres, M. A., Zeidan, A. M., Ito, R., Zhang, J., Rampersad, A., Sinsimer, D., Backstrom, J. T., Platzbecker, U., & Komrokji, R. S. (2021). Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood, . https://doi.org/10.1182/blood.2021012589
Garcia-Manero, Guillermo, et al. "Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021012589
Garcia-Manero G, Mufti Obe GJ, Fenaux P, Buckstein RJ, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2021 Nov 10; doi: 10.1182/blood.2021012589. Epub 2021 Nov 10. PMID: 34758066.
Copy Download .nbib Format: NLM
Incidence, clinical characteristics, and outcome after unexpected cardiac arrest among critically ill adults with COVID-19: insight from the multicenter prospective ACICOVID-19 registry.

Annals of intensive care

Chelly J, Plantefève G, Kamel T, Bruel C, Nseir S, Lai C, Cirillo G, Skripkina E, Ehrminger S, Berdaguer-Ferrari FD, Le Marec J, Paul M, Autret A, Deye N.
PMID: 34773516
Ann Intensive Care. 2021 Nov 13;11(1):155. doi: 10.1186/s13613-021-00945-y.

BACKGROUND: Initial reports have described the poor outcome of unexpected cardiac arrest (CA) in intensive care unit (ICU) among COVID-19 patients in China and the USA. However, there are scarce data on characteristics and outcomes of such CA patients...

Cite
Chelly J, Plantefève G, Kamel T, et al. Incidence, clinical characteristics, and outcome after unexpected cardiac arrest among critically ill adults with COVID-19: insight from the multicenter prospective ACICOVID-19 registry. Ann Intensive Care. 2021;11(1):155doi: 10.1186/s13613-021-00945-y.
Chelly, J., Plantefève, G., Kamel, T., Bruel, C., Nseir, S., Lai, C., Cirillo, G., Skripkina, E., Ehrminger, S., Berdaguer-Ferrari, F. D., Le Marec, J., Paul, M., Autret, A., Deye, N. (2021). Incidence, clinical characteristics, and outcome after unexpected cardiac arrest among critically ill adults with COVID-19: insight from the multicenter prospective ACICOVID-19 registry. Annals of intensive care, 11(1), 155. https://doi.org/10.1186/s13613-021-00945-y
Chelly, Jonathan, et al. "Incidence, clinical characteristics, and outcome after unexpected cardiac arrest among critically ill adults with COVID-19: insight from the multicenter prospective ACICOVID-19 registry." Annals of intensive care vol. 11,1 (2021): 155. doi: https://doi.org/10.1186/s13613-021-00945-y
Chelly J, Plantefève G, Kamel T, Bruel C, Nseir S, Lai C, Cirillo G, Skripkina E, Ehrminger S, Berdaguer-Ferrari FD, Le Marec J, Paul M, Autret A, Deye N. Incidence, clinical characteristics, and outcome after unexpected cardiac arrest among critically ill adults with COVID-19: insight from the multicenter prospective ACICOVID-19 registry. Ann Intensive Care. 2021 Nov 13;11(1):155. doi: 10.1186/s13613-021-00945-y. PMID: 34773516; PMCID: PMC8590126.
Copy Download .nbib Format: NLM
Preattentive processing of visually guided self-motion in humans and monkeys.

Progress in neurobiology

Schmitt C, Schwenk JCB, Schütz A, Churan J, Kaminiarz A, Bremmer F.
PMID: 34224808
Prog Neurobiol. 2021 Oct;205:102117. doi: 10.1016/j.pneurobio.2021.102117. Epub 2021 Jul 02.

The visually-based control of self-motion is a challenging task, requiring - if needed - immediate adjustments to keep on track. Accordingly, it would appear advantageous if the processing of self-motion direction (heading) was predictive, thereby accelerating the encoding of...

Cite
Schmitt C, Schwenk JCB, Schütz A, et al. Preattentive processing of visually guided self-motion in humans and monkeys. Prog Neurobiol. 2021;205:102117doi: 10.1016/j.pneurobio.2021.102117.
Schmitt, C., Schwenk, J. C. B., Schütz, A., Churan, J., Kaminiarz, A., & Bremmer, F. (2021). Preattentive processing of visually guided self-motion in humans and monkeys. Progress in neurobiology, 205102117. https://doi.org/10.1016/j.pneurobio.2021.102117
Schmitt, Constanze, et al. "Preattentive processing of visually guided self-motion in humans and monkeys." Progress in neurobiology vol. 205 (2021): 102117. doi: https://doi.org/10.1016/j.pneurobio.2021.102117
Schmitt C, Schwenk JCB, Schütz A, Churan J, Kaminiarz A, Bremmer F. Preattentive processing of visually guided self-motion in humans and monkeys. Prog Neurobiol. 2021 Oct;205:102117. doi: 10.1016/j.pneurobio.2021.102117. Epub 2021 Jul 02. PMID: 34224808.
Copy Download .nbib Format: NLM
Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics.

Preventive medicine

Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC.
PMID: 34762966
Prev Med. 2022 Jan;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08.

Since 2012, cervical cancer screening guidelines allow for choice of screening test for women age 30-65 years (i.e., Pap every 3 years or Pap with human papillomavirus co-testing every 5 years). Intended to give patients and providers options, this...

Cite
Haas JS, Cheng D, Yu L, et al. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2021;154:106871doi: 10.1016/j.ypmed.2021.106871.
Haas, J. S., Cheng, D., Yu, L., Atlas, S. J., Clark, C., Feldman, S., Silver, M. I., Kamineni, A., Chubak, J., Pocobelli, G., Tiro, J. A., & Kobrin, S. C. (2022). Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Preventive medicine, 154106871. https://doi.org/10.1016/j.ypmed.2021.106871
Haas, Jennifer S, et al. "Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics." Preventive medicine vol. 154 (2022): 106871. doi: https://doi.org/10.1016/j.ypmed.2021.106871
Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2022 Jan;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08. PMID: 34762966; PMCID: PMC8724456.
Copy Download .nbib Format: NLM
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Bone marrow transplantation

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.
PMID: 31092900
Bone Marrow Transplant. 2019 Nov;54(11):1868-1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15.

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell...

Cite
Kansagra AJ, Frey NV, Bar M, et al. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019;54(11):1868-1880doi: 10.1038/s41409-019-0451-2.
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., Chabannon, C., Perales, M. A., Hudecek, M., Aljurf, M., Andritsos, L., Barrett, J. A., Bachanova, V., Bonini, C., Ghobadi, A., Gill, S. I., Hill, J. A., Kenderian, S., Kebriaei, P., Nagler, A., Maloney, D., Liu, H. D., Shah, N. N., Kharfan-Dabaja, M. A., Shpall, E. J., Mufti, G. J., Johnston, L., Jacoby, E., Bazarbachi, A., DiPersio, J. F., Pavletic, S. Z., Porter, D. L., Grupp, S. A., Sadelain, M., Litzow, M. R., Mohty, M., & Hashmi, S. K. (2019). Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone marrow transplantation, 54(11), 1868-1880. https://doi.org/10.1038/s41409-019-0451-2
Kansagra, Ankit J, et al. "Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)." Bone marrow transplantation vol. 54,11 (2019): 1868-1880. doi: https://doi.org/10.1038/s41409-019-0451-2
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019 Nov;54(11):1868-1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15. PMID: 31092900; PMCID: PMC8268756.
Copy Download .nbib Format: NLM
Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature.

Case reports in endocrinology

Tzelepis EG, Barengolts E, Garzon S, Shulan J, Eisenberg Y.
PMID: 31007958
Case Rep Endocrinol. 2019 Mar 17;2019:7964126. doi: 10.1155/2019/7964126. eCollection 2019.

OBJECTIVE: To present a rare case of malignant struma ovarii (MSO) and synchronous thyroid cancer, review the medical literature, and present the latest trends in management.METHODS: The case of a woman with MSO and concomitant thyroid cancer is presented,...

Cite
Tzelepis EG, Barengolts E, Garzon S, et al. Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature. Case Rep Endocrinol. 2019;2019:7964126doi: 10.1155/2019/7964126.
Tzelepis, E. G., Barengolts, E., Garzon, S., Shulan, J., & Eisenberg, Y. (2019). Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature. Case reports in endocrinology, 20197964126. https://doi.org/10.1155/2019/7964126
Tzelepis, Elias G, et al. "Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature." Case reports in endocrinology vol. 2019 (2019): 7964126. doi: https://doi.org/10.1155/2019/7964126
Tzelepis EG, Barengolts E, Garzon S, Shulan J, Eisenberg Y. Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature. Case Rep Endocrinol. 2019 Mar 17;2019:7964126. doi: 10.1155/2019/7964126. eCollection 2019. PMID: 31007958; PMCID: PMC6441504.
Copy Download .nbib Format: NLM
Truncal blocks and teenager postoperative pain perception after laparoscopic surgical procedures.

Pain reports

Visoiu M, Chelly J, Kenkre T.
PMID: 31579855
Pain Rep. 2019 Jun 20;4(4):e763. doi: 10.1097/PR9.0000000000000763. eCollection 2019.

INTRODUCTION: The prevalence of moderate to severe pain is high in hospitalized teenage patients admitted to surgical services.OBJECTIVES: The aims of this study were to determine (1) the preoperative and postoperative factors influencing teenager postoperative pain perception; and (2)...

Cite
Visoiu M, Chelly J, Kenkre T. Truncal blocks and teenager postoperative pain perception after laparoscopic surgical procedures. Pain Rep. 2019;4(4):e763doi: 10.1097/PR9.0000000000000763.
Visoiu, M., Chelly, J., & Kenkre, T. (2019). Truncal blocks and teenager postoperative pain perception after laparoscopic surgical procedures. Pain reports, 4(4), e763. https://doi.org/10.1097/PR9.0000000000000763
Visoiu, Mihaela, et al. "Truncal blocks and teenager postoperative pain perception after laparoscopic surgical procedures." Pain reports vol. 4,4 (2019): e763. doi: https://doi.org/10.1097/PR9.0000000000000763
Visoiu M, Chelly J, Kenkre T. Truncal blocks and teenager postoperative pain perception after laparoscopic surgical procedures. Pain Rep. 2019 Jun 20;4(4):e763. doi: 10.1097/PR9.0000000000000763. eCollection 2019. PMID: 31579855; PMCID: PMC6728005.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 135 entries